Why the study?
What is the clinical role of genetic testing in hypertrophic cardiomyopathy?
What is the clinical role of genetic testing in hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Genetic testing in hypertrophic cardiomyopathy is currently essential for familial screening and identifying genocopies, and may soon guide disease stratification and targeted therapies.
Hypertrophic cardiomyopathy (HCM) is most commonly transmitted as an autosomal dominant trait, caused by mutations in genes encoding cardiac sarcomere proteins¹⁻³. Other inheritable causes of the disease include mutations in genes coding for proteins important in calcium handling or that form part of the cytoskeleton⁴⁻⁶. At present, the primary clinical role of genetic testing in HCM is to facilitate familial screening to allow the identification of individuals at risk of developing the disease⁷,⁸. It is also used to diagnose genocopies, such as lysosomal⁹⁻¹¹ and glycogen storage disease which have different treatment strategies, rates of disease progression and prognosis¹²⁻¹⁴. The role of genetic testing in predicting prognosis is limited at present, but emerging data suggest that knowledge of the genetic basis of disease will assume an important role in disease stratification¹⁵⁻¹⁷ and offer potential targets for disease-modifying therapy in the near future¹⁸.
No takes yet. Share an insight, caveat, or question.
Akhtar et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: